Although both the dose of AraC used in this dataset is at the high end of the doses we tested, as no datasets with a gradient of AraC concentrations are available, and the DHODH inhibition is performed with a different compound at a different timepoint to the one we used, the GSEA analysis demonstrates strong correlation between biological pathways activated in response to AraC and pyrimidine synthesis inhibitors in primary AML blasts and AML cell lines other than the ones used in this study. The gene discussed is DHODH; the disease is acute myeloid leukemia.